288 related articles for article (PubMed ID: 16925116)
1. In vitro inhibition of promyelocytic leukemia/retinoic acid receptor-alpha (PML/RARalpha) expression and leukemogenic activity by DNA/LNA chimeric antisense oligos.
Caprodossi S; Galluzzi L; Biagetti S; Della Chiara G; Pelicci PG; Magnani M; Fanelli M
Oncol Res; 2005; 16(3):157-66. PubMed ID: 16925116
[TBL] [Abstract][Full Text] [Related]
2. PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic leukemia cells.
Moog-Lutz C; Peterson EJ; Lutz PG; Eliason S; Cavé-Riant F; Singer A; Di Gioia Y; Dmowski S; Kamens J; Cayre YE; Koretzky G
J Biol Chem; 2001 Jun; 276(25):22375-81. PubMed ID: 11301322
[TBL] [Abstract][Full Text] [Related]
3. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
[TBL] [Abstract][Full Text] [Related]
4. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
[TBL] [Abstract][Full Text] [Related]
5. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
6. Differentiation response of acute promyelocytic leukemia cells and PML/RARa leukemogenic activity studies by real-time RT-PCR.
Caprodossi S; Pedinotti M; Amantini C; Santoni G; Minucci S; Pelicci PG; Fanelli M
Mol Biotechnol; 2005 Jul; 30(3):231-8. PubMed ID: 15988048
[TBL] [Abstract][Full Text] [Related]
7. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
[TBL] [Abstract][Full Text] [Related]
8. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
9. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
10. Annexin A2-S100A10 heterotetramer is upregulated by PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia.
Huang D; Yang Y; Sun J; Dong X; Wang J; Liu H; Lu C; Chen X; Shao J; Yan J
Front Med; 2017 Sep; 11(3):410-422. PubMed ID: 28687976
[TBL] [Abstract][Full Text] [Related]
11. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.
Dong S; Zhu J; Reid A; Strutt P; Guidez F; Zhong HJ; Wang ZY; Licht J; Waxman S; Chomienne C; Chen Z; Zelent A; Chen SJ
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3624-9. PubMed ID: 8622986
[TBL] [Abstract][Full Text] [Related]
12. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
[TBL] [Abstract][Full Text] [Related]
13. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.
He LZ; Tribioli C; Rivi R; Peruzzi D; Pelicci PG; Soares V; Cattoretti G; Pandolfi PP
Proc Natl Acad Sci U S A; 1997 May; 94(10):5302-7. PubMed ID: 9144232
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
Guo Y; Dolinko AV; Chinyengetere F; Stanton B; Bomberger JM; Demidenko E; Zhou DC; Gallagher R; Ma T; Galimberti F; Liu X; Sekula D; Freemantle S; Dmitrovsky E
Cancer Res; 2010 Dec; 70(23):9875-85. PubMed ID: 20935222
[TBL] [Abstract][Full Text] [Related]
15. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.
Kitareewan S; Pitha-Rowe I; Sekula D; Lowrey CH; Nemeth MJ; Golub TR; Freemantle SJ; Dmitrovsky E
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3806-11. PubMed ID: 11891284
[TBL] [Abstract][Full Text] [Related]
16. Altered nuclear cofactor switching in retinoic-resistant variants of the PML-RARα oncoprotein of acute promyelocytic leukemia.
Farris M; Lague A; Manuelyan Z; Statnekov J; Francklyn C
Proteins; 2012 Apr; 80(4):1095-109. PubMed ID: 22228505
[TBL] [Abstract][Full Text] [Related]
17. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia.
Takayama N; Kizaki M; Hida T; Kinjo K; Ikeda Y
Exp Hematol; 2001 Jul; 29(7):864-72. PubMed ID: 11438209
[TBL] [Abstract][Full Text] [Related]
18. Activation of
Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
[TBL] [Abstract][Full Text] [Related]
19. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
20. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha.
Occhionorelli M; Santoro F; Pallavicini I; Gruszka A; Moretti S; Bossi D; Viale A; Shing D; Ronzoni S; Muradore I; Soncini M; Pruneri G; Rafaniello P; Viale G; Pelicci PG; Minucci S
Leukemia; 2011 May; 25(5):814-20. PubMed ID: 21331069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
